These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 25941016)

  • 1. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
    Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
    Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
    Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC
    Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
    McGinley JS; Buse DC; Shulman KJ; Wirth RJ; Hugentobler E; Lipton RB
    Headache; 2019 Jul; 59(7):1002-1013. PubMed ID: 31062349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
    Cady R
    Expert Opin Drug Deliv; 2015; 12(9):1565-77. PubMed ID: 26119828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.
    Lipton RB; McGinley JS; Shulman KJ; Silberstein SD; Wirth RJ; Buse DC
    Headache; 2018 Feb; 58(2):229-242. PubMed ID: 29034453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.
    Silberstein SD
    Expert Opin Drug Saf; 2018 Jan; 17(1):89-97. PubMed ID: 28994319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
    Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
    Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.
    Silberstein S
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):821-832. PubMed ID: 28605258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence.
    Winner P; Linder S; Hershey AD
    Headache; 2015 Apr; 55(4):519-28. PubMed ID: 25881677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P; Rothner AD; Wooten JD; Webster C; Ames M
    Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
    Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
    Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.
    Cady RK; Munjal S; Cady RJ; Manley HR; Brand-Schieber E
    J Headache Pain; 2017 Dec; 18(1):17. PubMed ID: 28176235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
    Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
    Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
    Schulman EA
    Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.